Celltrion Healthcare Co (091990.KQ) Stock Price
Celltrion Healthcare Co Price
Revenue has compounded at 23.7% per year over the past 15 years to 2.22 T KRW. Earnings per share have grown at 20.3% per year over the last 14 years. Celltrion Healthcare Co's net margin stands at 1.9%, down from 5.9% several years earlier. Celltrion Healthcare Co currently offers a dividend yield of about 0.16%. The payout ratio is around 14% of earnings.
Celltrion Healthcare Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Celltrion Healthcare Co business model & stock analysis
Frequently asked questions about Celltrion Healthcare Co
The business model of Celltrion Healthcare Co Ltd is focused on the development, manufacturing, and commercialization of biopharmaceutical products. As a leading biopharmaceutical company, Celltrion Healthcare specializes in the production of biosimilar drugs, which are cost-effective alternatives to existing biologic medications. By leveraging its expertise in biotechnology, Celltrion Healthcare aims to provide affordable and accessible treatments for patients worldwide. Through strategic partnerships and continuous research and development, the company aims to expand its product portfolio and enhance patient care in various therapeutic areas.
Celltrion Healthcare Co Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Celltrion Healthcare Co Ltd in the market are multinational pharmaceutical companies such as Roche, Novartis, and Johnson & Johnson.
Celltrion Healthcare Co Ltd is a global biopharmaceutical company that specializes in the development and distribution of innovative and biosimilar therapeutics. Founded in 2002, the company has made substantial advancements in the healthcare industry. Celltrion Healthcare focuses on the research and production of high-quality drugs to provide affordable treatment options for patients worldwide. With a strong commitment to research and development, the company has successfully launched multiple biosimilar products, catering to various therapeutic areas. Celltrion Healthcare Co Ltd continues to excel in its mission to improve healthcare accessibility and enhance patients' quality of life through innovative medical solutions.
Celltrion Healthcare Co Ltd has achieved significant milestones in its history. The company has been successful in developing and commercializing innovative biosimilar products, contributing to improved access to affordable biologics for patients worldwide. Additionally, Celltrion Healthcare Co Ltd has received regulatory approvals for various biosimilars, including those for autoimmune diseases and oncology. Moreover, the company has expanded its global presence by establishing partnerships and collaborations with leading pharmaceutical companies. These achievements highlight Celltrion Healthcare Co Ltd's commitment to advancing healthcare through the development of high-quality biosimilars and innovative treatments for patients across the globe.
Celltrion Healthcare Co Ltd primarily operates in various countries and regions globally. The company has a significant presence in South Korea, where it is headquartered. Additionally, Celltrion Healthcare has expanded its operations in various international markets, including the United States, Europe, Asia Pacific, and Latin America. With its strong international footprint, Celltrion Healthcare Co Ltd strives to provide innovative healthcare solutions and enhance access to advanced treatments for patients across different regions and markets.
Celltrion Healthcare Co Ltd represents values of innovation, dedication, and patient-centricity. As a leading global biopharmaceutical company, Celltrion Healthcare is committed to developing and providing affordable, high-quality biopharmaceutical products for patients across the world. Their corporate philosophy revolves around improving global healthcare by harnessing the power of advanced biotechnology. Through extensive research and development, Celltrion Healthcare aims to address unmet medical needs and contribute to the well-being of individuals. With their strong focus on innovation and patient well-being, Celltrion Healthcare remains dedicated to the advancement of healthcare globally.
16 analysts currently rate the Celltrion Healthcare Co stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Celltrion Healthcare Co to generate revenue of 3.97 T KRW and earnings per share of 2,617.28 KRW.
Converted at the current exchange rate, the Celltrion Healthcare Co share trades at 50.83 EUR (75,900.00 KRW).
The Celltrion Healthcare Co share (091990.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (091990.KQ).
Celltrion Healthcare Co Ltd is a South Korean company specialized in the development, manufacturing, and marketing of biological products and drugs for various diseases and conditions.
The expected revenue of Celltrion Healthcare Co is 3.97 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Celltrion Healthcare Co is 422.20 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Celltrion Healthcare Co is currently 29.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Celltrion Healthcare Co stock.
The price-to-sales ratio (P/S) of Celltrion Healthcare Co is currently 3.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Celltrion Healthcare Co stock.
The Eulerpool Quality Score for Celltrion Healthcare Co is 5/10.
The ISIN of Celltrion Healthcare Co is KR7091990002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Celltrion Healthcare Co is 091990.KQ. The ticker symbol is used to trade Celltrion Healthcare Co shares on the stock exchange.
Celltrion Healthcare Co stock
Celltrion Healthcare Co Peer Group
Celltrion Healthcare Co Ticker
Celltrion Healthcare Co FIGI
All fundamentals and in-depth analysis of Celltrion Healthcare Co
Our stock analysis for Celltrion Healthcare Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celltrion Healthcare Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.